Hypermethylation of promoters of RASSF1 and MGMT genes appears to be an epigenetic marker of MEN1 insulinomas or MEN1 NF-pNETs, respectively, suggesting that they could be promising selective therapeutic targets for these two types of pancreatic tumors. This evidence concerns the gene MGMT and pancreatic insulinoma.